Thomas P. Frye, DO, presented “Point Counterpoint: MRI” during the 2023 Frontiers in Oncologic Prostate Care and Ablative Local Therapy symposium on November 10, 2023, in Chicago, Illinois.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Frye, Thomas P. “Point Counterpoint: MRI.” November, 2023. Accessed Nov 2024. https://grandroundsinurology.com/point-counterpoint-mri/
Point Counterpoint: MRI – Summary
Thomas P. Frye, DO, argues in favor of multiparametric magnetic resonance imaging (mpMRI) over micro ultrasound (microUS) for prostate imaging. He begins by stating the underlying goals of prostate imaging in the context of triaging in urologic oncology.
Dr. Frye then turns to the lack of data in support of microUS over mpMRI. He highlights that prostate imaging from microUS lacks the scale and reliable interpretability of mpMRI.
Dr. Frye supports the effectiveness of mpMRI in detecting clinically significant prostate cancer with data from the PROMIS and PRECISION studies. He notes that the use of mpMRI in screening can prevent unnecessary biopsies of insignificant cancers.
He concludes by reviewing weaknesses in recent studies of microUS. He presents a clinical analysis of microUS which demonstrated the superiority of conventional imaging (TRUS) and mpMRI over microUS.
Frontiers in Oncologic Prostate Care and Ablative Local Therapy (FOCAL) is an outstanding program on prostate imaging, transperineal interventions, and ablative treatments for prostate cancer and benign prostatic hyperplasia. Bringing together community-based, academic, and industry partners, FOCAL offers lectures by world-renowned faculty and hands-on training workshops on in-office transperineal interventions, fusion-guided prostate ablation and state-of-the-art BPH management with novel technologies.
ABOUT THE AUTHOR
Doctor Thomas Frye currently serves as Associate Professor of Urology and Vice Chair of Clinical Affairs for the Department of Urology at the University of Rochester Medical Center. Dr. Frye, is a Urologic Oncologist who specializes in both minimally invasive urologic oncology (robotic surgery of prostate and kidney cancers), and advanced open pelvic and retroperitoneal cancer surgery. He has a special interest and expertise in the management of localized prostate cancer with focal therapy. Dr. Frye has the most comprehensive focal therapy program in upstate New York and offers High Intensity Focused Ultrasound (HIFU), cryotherapy, as well as other ablative technologies. He also participates in national clinical trials evaluating the efficacy of focal therapy for prostate cancer.
Dr. Frye was the valedictorian of his class where he graduated with a Doctor of Osteopathy degree from Midwestern University, Chicago College of Osteopathic Medicine. He went on to complete his urology residency at Southern Illinois University School of Medicine. Dr. Frye was chosen for the prestigious fellowship training in Urologic Oncology within The National Cancer Institute at the National Institutes of Health (NIH) in Bethesda, Maryland.
Dr. Frye’s research projects focus on optimizing the screening, diagnosis and treatment of men with prostate cancer. During his fellowship, he worked extensively in refining the use of prostate MRIs in men on active surveillance. Dr. Frye's clinical research interest also includes advanced imaging for prostate cancer as well as focal therapy of prostate cancer.
Dr. Frye is involved in multiple specialty societies including the American Urological Association (AUA), Society of Urologic Oncology (SUO), American Society of Clinical Oncology, and Focal Therapy Society.
